Self-pay tiers, ketamine/TMS feasibility, and group therapy economics are the three biggest levers in independent psychiatry today. We model all three with conservative ramp curves.
Every report compares your numbers against published peer data. Sources include MGMA, CMS, and specialty-society reports.
| Metric | Reference value | Source |
|---|---|---|
| No-show rate, behavioral health median | 18–24% | Industry analysis |
| Therapist utilization, median | 68–76% | MGMA mental health |
| Cash revenue per hour vs. commercial, median delta | +$45–$95 | Industry survey |
You don't need all four. Start with the one we recommend first — most owners stop there because it surfaces enough to act on for the next 90 days.
Benchmarks your payer mix against peers and flags the contracts most worth renegotiating.
Go/no-go assessment for a service line you're considering adding.
Ranks your top 8–10 revenue expansion opportunities by specialty, staff, and payer mix.
Identifies whether your NPs, PAs, and licensed staff are billing at full scope.
Pulled from patterns we see across audits. Your numbers will differ, but the categories are remarkably consistent.
Yes, with separate capex, training, and credentialing timelines. The feasibility report ranks them by NPV against your specific panel size and payer mix.